HAYA Therapeutics

About:

HAYA Therapeutics is a biopharmaceutical company that specializes in treating heart failure diseases.

Top Investors: Eli Lilly, Venture Kick, Apollo Health Ventures, Broadview Ventures, MassChallenge

Description:

HAYA Therapeutics is a developer of RNA-based therapeutics created to treat heart failure. The company's therapeutics utilizes biopharmaceutical therapy to target a heart specific regulator of fibrosis, the long noncoding RNA, enabling physicians to to block myocardial fibrosis and treat heart failure.

Total Funding Amount:

$1.04B

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Lausanne, Vaud, Switzerland

Founded Date:

2017-01-01

Founders:

Daniel Blessing, Samir Ounzain

Number of Employees:

11-50